Last reviewed · How we verify

Vehicle of ADX-102 Topical Dermal Cream

Aldeyra Therapeutics, Inc. · Phase 3 active Small molecule

Vehicle of ADX-102 Topical Dermal Cream is a Complement inhibitor Small molecule drug developed by Aldeyra Therapeutics, Inc.. It is currently in Phase 3 development for Vernal keratoconjunctivitis, Atopic keratoconjunctivitis.

ADX-102 is a topical dermal cream that targets the complement pathway to reduce inflammation.

ADX-102 is a topical dermal cream that targets the complement pathway to reduce inflammation. Used for Vernal keratoconjunctivitis, Atopic keratoconjunctivitis.

At a glance

Generic nameVehicle of ADX-102 Topical Dermal Cream
SponsorAldeyra Therapeutics, Inc.
Drug classComplement inhibitor
TargetComplement component 3 (C3)
ModalitySmall molecule
Therapeutic areaOphthalmology, Dermatology
PhasePhase 3

Mechanism of action

By inhibiting the complement pathway, ADX-102 aims to reduce inflammation and alleviate symptoms associated with various ocular and skin conditions. This mechanism is particularly relevant for conditions characterized by complement-mediated inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vehicle of ADX-102 Topical Dermal Cream

What is Vehicle of ADX-102 Topical Dermal Cream?

Vehicle of ADX-102 Topical Dermal Cream is a Complement inhibitor drug developed by Aldeyra Therapeutics, Inc., indicated for Vernal keratoconjunctivitis, Atopic keratoconjunctivitis.

How does Vehicle of ADX-102 Topical Dermal Cream work?

ADX-102 is a topical dermal cream that targets the complement pathway to reduce inflammation.

What is Vehicle of ADX-102 Topical Dermal Cream used for?

Vehicle of ADX-102 Topical Dermal Cream is indicated for Vernal keratoconjunctivitis, Atopic keratoconjunctivitis.

Who makes Vehicle of ADX-102 Topical Dermal Cream?

Vehicle of ADX-102 Topical Dermal Cream is developed by Aldeyra Therapeutics, Inc. (see full Aldeyra Therapeutics, Inc. pipeline at /company/aldeyra-therapeutics-inc).

What drug class is Vehicle of ADX-102 Topical Dermal Cream in?

Vehicle of ADX-102 Topical Dermal Cream belongs to the Complement inhibitor class. See all Complement inhibitor drugs at /class/complement-inhibitor.

What development phase is Vehicle of ADX-102 Topical Dermal Cream in?

Vehicle of ADX-102 Topical Dermal Cream is in Phase 3.

What are the side effects of Vehicle of ADX-102 Topical Dermal Cream?

Common side effects of Vehicle of ADX-102 Topical Dermal Cream include Eye irritation, Skin irritation.

What does Vehicle of ADX-102 Topical Dermal Cream target?

Vehicle of ADX-102 Topical Dermal Cream targets Complement component 3 (C3) and is a Complement inhibitor.

Related